Baoxiang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Baoxiang Chen has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Congqing Jiang
Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
16 shared publications - Jianhong Zhao
Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
16 shared publications - Xianghai Ren
Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
16 shared publications - Jinfang Zhang
Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China
15 shared publications - Haisheng Yu
Department of Radiation and Medical Oncology, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Provincial Clinical Research Center for Cancer, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China
14 shared publications - Jing Dai
10Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, China
14 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
In vivo CRISPR screens identify dual functions of DNMT3A in mediating tumor immune evasion
Cancer immunotherapy has achieved remarkable clinical efficacy across multiple cancers but remains ineffective for most patients, and the mechanisms underlying resistance remain incompletely understood. Here, we perform in vivo CRISPR-Cas9 screens in female mice and identify DNA methyltransferase 3 A (DNMT3A) as a key driver of tumor immune evasion through both methyltransferase-dependent and -independent mechanisms. DNMT3A represses TNFRSF1A and TNFRSF1B expression, enabling tumor cells to evade TNFα-induced killing. Independently of its methyltransferase activity, DNMT3A interacts with NFYA to activate cholesterol biosynthesis, leading to zymosterol accumulation in tumor interstitial fluid. Zymosterol impairs SREBP2 cleavage and promotes HMGCR degradation in CD8⁺ T cells, thereby suppressing cholesterol biosynthesis and compromising their antitumor effector functions. Targeting DNMT3A with antisense oligonucleotides overcomes resistance to immune checkpoint blockade. Collectively, these findings establish DNMT3A as an integrated epigenetic and metabolic checkpoint in tumor immune evasion and a potential target for immunotherapy.
- 11 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIn vivo CRISPR screens identify dual functions of DNMT3A in mediating tumor immune evasion
Cancer immunotherapy has achieved remarkable clinical efficacy across multiple cancers but remains ineffective for most patients, and the mechanisms underlying resistance remain incompletely understood. Here, we perform in vivo CRISPR-Cas9 screens in female mice and identify DNA methyltransferase 3 A (DNMT3A) as a key driver of tumor immune evasion through both methyltransferase-dependent and -independent mechanisms. DNMT3A represses TNFRSF1A and TNFRSF1B expression, enabling tumor cells to evade TNFα-induced killing. Independently of its methyltransferase activity, DNMT3A interacts with NFYA to activate cholesterol biosynthesis, leading to zymosterol accumulation in tumor interstitial fluid. Zymosterol impairs SREBP2 cleavage and promotes HMGCR degradation in CD8⁺ T cells, thereby suppressing cholesterol biosynthesis and compromising their antitumor effector functions. Targeting DNMT3A with antisense oligonucleotides overcomes resistance to immune checkpoint blockade. Collectively, these findings establish DNMT3A as an integrated epigenetic and metabolic checkpoint in tumor immune evasion and a potential target for immunotherapy.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
AMPK-mediated ChREBP phosphorylation inhibits the expression of chemokine and choline metabolism genes or proteins.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
AMPK-mediated ChREBP phosphorylation inhibits the expression of chemokine and choline metabolism genes or proteins.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
Hyperexpression of ChREBP is associated with a poor prognosis and “immune deserts” phenotype in CRC.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
Hyperexpression of ChREBP is associated with a poor prognosis and “immune deserts” phenotype in CRC.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP promotes chemokine production and recruits TAMs to induce tumor immune evasion.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP promotes chemokine production and recruits TAMs to induce tumor immune evasion.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
Choline induced macrophages to acquire an immunostimulatory phenotype.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
Choline induced macrophages to acquire an immunostimulatory phenotype.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
The differential metabolites identified by LC-MS from shChrebp or shNC MC38 tumors.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
The differential metabolites identified by LC-MS from shChrebp or shNC MC38 tumors.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
AMPK activation enhances the efficacy of anti-PD-L1 therapy by increasing phosphorylation of ChREBP.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
AMPK activation enhances the efficacy of anti-PD-L1 therapy by increasing phosphorylation of ChREBP.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
Gating and sorting strategies.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
Gating and sorting strategies.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP interacts with SP1 to promote the expression of chemokine and choline metabolism genes.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP interacts with SP1 to promote the expression of chemokine and choline metabolism genes.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP interacts with SP1 and promotes SP1 binding to chemokine and choline metabolism gene promoters.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion
ChREBP interacts with SP1 and promotes SP1 binding to chemokine and choline metabolism gene promoters.